Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

AZN

Astrazeneca plc ADR

Nov 28 • 04:00PM ET

92.72

-0.60 -0.64 %

Healthcare • Drug Manufacturers - General • United Kingdom • NASD

Peers: ABBV PFE JNJ MRK NVS BMY GSK SNY LLY AMGN

| Held by: QQQ QQQM PVAL CGGO DIHP DFIC PPH AVDE TQQQ FVD

Scroll to Statements

Index	NDX	P/E	30.75	EPS (ttm)	3.01	Insider Own	0.03%	Shs Outstand	3.10B	Perf Week	4.56%
Market Cap	287.48B	Forward P/E	17.95	EPS next Y	5.17	Insider Trans	0.00%	Shs Float	3.10B	Perf Month	12.76%
Enterprise Value	312.02B	PEG	2.51	EPS next Q	1.07	Inst Own	16.15%	Short Float	0.32%	Perf Quarter	16.05%
Income	9.41B	P/S	4.95	EPS this Y	11.77%	Inst Trans	0.31%	Short Ratio	2.02	Perf Half Y	27.31%
Sales	58.12B	P/B	6.26	EPS next Y	12.59%	ROA	8.58%	Short Interest	9.97M	Perf YTD	41.51%
Book/sh	14.80	P/C	35.14	EPS next 5Y	12.23%	ROE	21.73%	52W High	94.01 -1.38%	Perf Year	39.64%
Cash/sh	2.64	P/FCF	22.16	EPS past 3/5Y	285.92% 34.53%	ROIC	13.08%	52W Low	61.24 51.40%	Perf 3Y	40.48%
Dividend Est.	1.63 (1.75%)	EV/EBITDA	16.19	Sales past 3/5Y	12.66% 17.18%	Gross Margin	73.25%	Volatility	1.53% 1.61%	Perf 5Y	67.67%
Dividend TTM	1.56 (1.69%)	EV/Sales	5.37	EPS Y/Y TTM	44.28%	Oper. Margin	21.89%	ATR (14)	1.62	Perf 10Y	172.63%
Dividend Ex-Date	Aug 08, 2025	Quick Ratio	0.69	Sales Y/Y TTM	12.95%	Profit Margin	16.19%	RSI (14)	72.16	Recom	1.60
Dividend Gr. 3/5Y	2.54% 2.10%	Current Ratio	0.88	EPS Q/Q	74.53%	SMA20	5.60%	Beta	0.32	Target Price	96.25
Payout	66.95%	Debt/Eq	0.71	Sales Q/Q	10.18%	SMA50	10.11%	Rel Volume	0.76	Prev Close	93.32
Employees	94300	LT Debt/Eq	0.57	Earnings	Nov 06 BMO	SMA200	21.95%	Avg Volume	4.93M	Price	92.72
IPO	May 12, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.00% 0.00%	Trades		Volume	3,747,969	Change	-0.64%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-27-25	Resumed	Jefferies	Buy
Oct-16-25	Downgrade	Deutsche Bank	Hold → Sell
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$75
Feb-13-25	Upgrade	UBS	Neutral → Buy
Feb-12-25	Initiated	Morgan Stanley	Overweight
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy	$97
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight	$85
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold	$78.50 → $70
Dec-18-23	Initiated	HSBC Securities	Buy	$78
Sep-25-23	Upgrade	Jefferies	Hold → Buy	$66.50 → $80
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight

Show Previous Ratings

Nov-28-25 10:03AM	JNJ's Oncology Momentum Builds as It Chases $50B Goal by 2030 (Zacks)
09:45AM	Here's Why Astrazeneca (AZN) is a Strong Growth Stock (Zacks)
Nov-27-25 09:45AM	AstraZeneca or Merck: Which Oncology Giant Has the Edge? (Zacks)
09:40AM	Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term (Zacks)
Nov-26-25 04:11PM	Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied (Investor's Business Daily)
09:49AM	Loading…
09:49AM	Will Soft Gardasil Demand Continue to Dampen Merck's Top Line? (Zacks)
Nov-25-25 07:57PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
07:24AM	J&J Up Around 17% in 3 Months: Should You Buy, Sell or Hold the Stock? (Zacks)
Nov-24-25 06:21AM	AstraZeneca to expand biomanufacturing in Maryland, US (Pharmaceutical Business Review)
Nov-21-25 08:28PM	AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer (CNBC TV)
06:23PM	Why AstraZeneca Stock Bumped Higher Today (Motley Fool)
02:37PM	Fighting Cancer With 'Smart Bombs.' What New Treatments Mean For Wall Street. (Investor's Business Daily)
02:05PM	AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalyzing economic growth (Business Wire)
10:30AM	Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3? (Zacks)
10:15AM	AZN Wins FDA Nod for Expanded Use of Rare Disease Drug, Koselugo (Zacks)
07:41AM	Loading…
07:41AM	PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms (Zacks)
Nov-20-25 01:57PM	AstraZeneca Wins FDA Nod For Koselugo In Adult NF1 (GuruFocus.com)
Nov-19-25 09:08AM	AbbVie Stock Rebounds After Q3 Dip: Time to Buy, Hold or Sell? (Zacks)
Nov-18-25 04:21PM	Why biotech and drug stocks are on the mend even though the rest of the market is hurting (MarketWatch)
06:30AM	Johnson & Johnson Buys Prostate Cancer Treatment-Maker Halda for $3.1 Billion (The Daily Upside)
Nov-17-25 09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-13-25 12:14PM	Pfizer CEO Albert Bourla says aggressive bid for Metsera reflects company's 'right to win' obesity market (Yahoo Finance)
10:36AM	IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
Nov-12-25 04:30PM	BeOne, IBD Stock Of The Day, Breaks Out As It Takes On Cancer Giants J&J, AbbVie (Investor's Business Daily)
01:47PM	The FDA Has a New Drug Chief. What it Means for Biotech Stocks. (Barrons.com)
12:54PM	IBD Stock Of The Day BeOne Breaks Out As It Takes On Cancer Giants J&J, AbbVie (Investor's Business Daily)
09:45AM	Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term (Zacks)
Nov-11-25 09:56AM	IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars (Zacks)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Nov-10-25 05:20PM	Why AstraZeneca Stock Was a Winner Today (Motley Fool)
04:33PM	Loading…
Nov-09-25 04:33PM	Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial (Business Wire)
Nov-07-25 11:28AM	Pfizer Discusses Drug Pricing Deal, Metsera Buyout Dispute on Q3 Call (Zacks)
09:38AM	Analyst Report: AstraZeneca PLC (Morningstar Research)
06:30AM	CEO Says AstraZeneca Can Absorb Costs of Trump-Driven US Deals (The Daily Upside)
03:32AM	Company News for Nov 7, 2025 (Zacks)
Nov-06-25 04:42PM	Why AstraZeneca Stock Topped the Market on Thursday (Motley Fool)
04:08PM	AstraZeneca Bounds Into A Chase Zone As Cancer Drugs Drive Sales Beat (Investor's Business Daily)
02:37PM	Novo Nordisk and Eli Lilly Can Sell Their Weight-Loss Drugs to Medicare Market (Barrons.com)
02:05PM	AstraZeneca PLC (AZN) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances (GuruFocus.com)
01:42PM	Stocks in Focus Globally: Nissan, ArcelorMittal, AstraZeneca (The Wall Street Journal)
11:45AM	AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform (Zacks)
11:41AM	AstraZeneca Stuns Wall Street With Surprise Profit Surge (GuruFocus.com)
11:14AM	Earnings Data Deluge (Zacks)
10:36AM	Pre-Markets Improve on Big Earnings Morning (Zacks)
09:30AM	Compared to Estimates, Astrazeneca (AZN) Q3 Earnings: A Look at Key Metrics (Zacks)
08:45AM	Stocks Around the World in Focus: Nissan, ArcelorMittal, Deutsche Boerse (The Wall Street Journal)
08:34AM	AstraZeneca Shares Jump; Drugmaker Keeps Outlook As Cancer Drug Sales Soar (Investor's Business Daily)
07:51AM	AstraZeneca CEO bullish on record revenue numbers and US growth (Yahoo Finance Video)
02:59AM	AstraZeneca beats forecasts in Q3, reaffirms full-year guidance (Investing.com)
02:39AM	AstraZeneca Revenue Climbs on Pipeline Strength (The Wall Street Journal)
Nov-05-25 07:00PM	Tesla shareholder vote, Fed talk, mortgage rates: What to Watch (Yahoo Finance Video)
01:54PM	Eli Lilly Stock Sees RS Rating Rise To 77 (Investor's Business Daily)
11:37AM	Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up (Zacks)
Nov-04-25 11:15AM	Pfizer Q3 Earnings Beat Estimates, Sales Decline as COVID Demand Cools (Zacks)
Oct-31-25 07:00PM	SNAP benefits expire, open enrollment, earnings: What to Watch (Yahoo Finance Video)
02:00PM	Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings? (Zacks)
11:07AM	Pfizer Q3 Earnings Loom: Buy, Sell or Hold PFE Stock Ahead of Results? (Zacks)
Oct-30-25 01:14PM	Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook (Zacks)
12:41PM	MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down (Zacks)
09:22AM	Eli Lilly Stock Rises on Earnings as Investors Await Trump Drug Pricing Deal (Barrons.com)
Oct-29-25 04:45PM	Eli Lilly Reports Earnings Thursday as Investors Await Trump Drug Pricing Deal (Barrons.com)
Oct-28-25 06:15PM	Astrazeneca (AZN) Stock Declines While Market Improves: Some Information for Investors (Zacks)
12:37PM	Buy, Sell or Hold MRK Stock Ahead of Q3 Earnings? Things to Know (Zacks)
Oct-24-25 04:12PM	Sanofi Jumps As Dupixent Nears $5 Billion In Sales; Trump Drug Talks Continue (Investor's Business Daily)
12:07PM	A GSK Cancer Drug Is Making a Comeback. Its So-So News for the Stock. (Barrons.com)
10:01AM	Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline (Zacks)
09:29AM	Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings (Zacks)
Oct-23-25 11:13AM	3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years (MarketBeat)
10:39AM	Lilly Up 10% in a Month: Should You Buy, Sell or Hold the Stock? (Zacks)
05:24AM	Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue (The Wall Street Journal)
Oct-22-25 10:35PM	J.P. Morgan Maintains a Buy Rating on AstraZeneca PLC (AZN), Sets a £140 PT (Insider Monkey)
02:31PM	AstraZeneca PLC (AZN): A Bull Case Theory (Insider Monkey)
10:29AM	AbbVie Up More Than 30% in 6 Months: How to Play the Stock (Zacks)
Oct-21-25 10:39AM	Did IonQ Just Unlock Quantum Computings True Potential And a Massive Stock Rally? (24/7 Wall St.)
06:51AM	The Zacks Analyst Blog Highlights AstraZeneca, RTX, Applied Materials, Park Aerospace and NetSol Technologies (Zacks)
Oct-20-25 04:28PM	Top Research Reports for AstraZeneca, RTX & Applied Materials (Zacks)
03:45PM	AstraZeneca's Cancer Breakthrough: Enhertu Data Sparks New Hope for Early Breast Cancer Cure (GuruFocus.com)
10:10AM	Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings (Zacks)
09:50AM	Here's Why Astrazeneca (AZN) is a Strong Momentum Stock (Zacks)
06:53AM	AstraZeneca hails major breakthroughs with breast-cancer drugs (MarketWatch)
Oct-19-25 07:00AM	DATROWAY (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option (Business Wire)
Oct-18-25 10:35AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial (Business Wire)
10:30AM	AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash (Investor's Business Daily)
10:30AM	ENHERTU Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial (Business Wire)
10:30AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial (Business Wire)
Oct-17-25 06:15PM	Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know (Zacks)
04:17PM	TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps (Business Wire)
12:20PM	Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings? (Zacks)
12:11PM	Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings? (Zacks)
08:10AM	IMFINZI (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial (Business Wire)
08:00AM	IMFINZI (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial (Business Wire)
Oct-16-25 01:55PM	LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins (Zacks)
09:48AM	2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades (Motley Fool)
07:23AM	AstraZeneca cut to Sell by Deutsche Bank on pipeline doubts, patent risk (Investing.com)
Oct-15-25 01:19PM	Trump Locks In AstraZeneca Deal to Slash Medicaid Drug Prices -- Big Pharma Faces New Reality (GuruFocus.com)
10:00AM	AstraZeneca unveils expanded manufacturing facility in Texas (Business Wire)
09:20AM	Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX? (Zacks)
Oct-14-25 09:45AM	Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
08:43AM	Johnson & Johnson Earnings Beat Estimates. Why the Stock Is Dropping. (Barrons.com)
06:20AM	Johnson & Johnson Says It Will Spin Off Orthopaedics Business (Barrons.com)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company's history roots back to the year 1913 when Astra business was formed. AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group PLC. The company is headquartered in Cambridge, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ARADHANA SARIN	Officer	Nov 12 '25	Proposed Sale	88.88	15,000	1,333,200		Nov 12 05:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

AZN

Astrazeneca plc ADR

Upgrade your FINVIZ experience